BaseClear to Bundle Illumina Data with CLC bio's Software for Next Generation Sequencing Data Analysis
News Jul 16, 2009
CLC bio has announced that the premier Dutch sequencing service center, BaseClear, will provide all customers receiving Next Generation Sequencing data with a license for CLC Genomics Workbench for assembly and downstream sequence analyzes.
Commercial Director at BaseClear, Bas Reichert, states, "In order for our customers to get the best possible information out of the Next Generation Sequencing data we produce with our Illumina Genome Analyzer II, we have been looking for a user-friendly solution with a relatively easy learning curve to bundle together with the data. With CLC bio's Genomics Workbench we have found that, and that increased scientific value for our customers is a compelling argument for us to enter an agreement of this type with CLC bio."
Director of Sales, Europe, The Middle East & Africa, at CLC bio, Michel Seidelin, PhD, continues, "Through their excellent service, BaseClear has for many years been the preferred sequencing partner for BeNeLux academic and non-academic laboratories. We’re pleased that BaseClear's Next Generation Sequencing customers now will be able to use the world's most user-friendly and comprehensive desktop program, CLC Genomics Workbench, for analysis and visualization of their genomics, transcriptomics, and epigenomics data. This will enable BaseClear's customers to easily assemble, visualize, and perform various downstream analyses of their Next Generation Sequencing data, helping them to rapidly focus on interpreting the biological relevance of their data."
This partnership between CLC bio and BaseClear is the first of many sequencing service centers projected to offer similar services.
Computer bits are binary, with a value of 0 or 1. By contrast, neurons in the brain can have all kinds of different internal states, depending on the input that they received. This allows the brain to process information in a more energy-efficient manner than a computer. A new study hopes to bring the two closer together.
MIT researchers have developed a cryptographic system that could help neural networks identify promising drug candidates in massive pharmacological datasets, while keeping the data private. Secure computation done at such a massive scale could enable broad pooling of sensitive pharmacological data for predictive drug discovery.